Generics BulletinZydus Lifesciences is making its foray into the global biologics contract development and manufacturing organization (CDMO) space while securing a strategic foothold in the US for biologics manufactur
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Will Try Camurus’s FluidCrystal D
Generics BulletinZydus Lifesciences seems unfazed by the prospect of another round of litigation in the US due in February 2026 over a generic to Astellas Pharma’s Myrbetriq (mirabegron) that both Zydus and compatriot
ScripEli Lilly’s blockbuster obesity and type 2 diabetes therapy, Mounjaro (tirzepatide) has made its India debut throwing down the gauntlet to rival Novo Nordisk, currently in the wings with Wegovy (injec